It is important for clinicians to be aware of the updated criteria to appropriately select patients who are sensitive to HER2-targeted agents; to stay up-to-date with evolving treatment strategies; to understand how to choose optimal treatment based on patient preference, toxicities, and drug availability; and to effectively evaluate patients during therapies and manage any therapy-related adverse effects.
For patients with advanced RCC, several factors are taken into consideration to help determine which systemic regimen to consider in the first-line and subsequent line therapy. It is important for clinicians to understand when to use regimens for their patient’s unique clinical situation and how to treatment for patients with metastatic RCC requiring second, third, fourth, or further lines of therapy.
Minimally invasive surgical techniques for endometrial cancers, particularly robotic-assisted laparoscopy, have been shown to decrease surgical morbidity and improve 30-day postoperative outcomes for appropriately selected patients with endometrial cancer. Despite evidence of improved outcomes, disparities persist in awareness of and access to minimally invasive surgery.

The Emerging Role of Tumor and Germline Genetic Testing and the Treatment of Advanced Disease

Case managers and medical directors need to be familiar with all the aspects of clinical management including diagnosis, prognostic stratification, treatment options, assessment of response to treatment, supportive care and survivorship care.

Pages

Subscribe to RSS - Live Webinar